Guanfacine Extended Release
Treatment for Adhd
Typical Dosage: 1-7mg daily
Effectiveness
55%
Safety Score
65%
Clinical Trials
18
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
1-7mg daily
Time to Effect
1-2 weeks for initial effects, 3-4 weeks for full effect
Treatment Duration
Long-term (as needed)
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$700
Monitoring:$250
Side Effect Mgmt:$50
Total Annual:$1,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$33,333/QALY
QALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$2,500
Cost per Remission
$6,666.67
Guanfacine Extended Release Outcomes
for Adhd
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+40%
Remission Rate
+15%
Common Side Effects
Sedation/somnolence
+25%
Fatigue
+15%
Dizziness
+12%
Headache
+10%
Abdominal pain
+7%
Hypotension/bradycardia
+6%
Sources:
Active Clinical Trials
1 active trial recruiting for Guanfacine Extended Release in Adhd
Treating Young Children With Attention Deficit Hyperactivity Disorder
NCT07300956NOT YET RECRUITINGPHASE4
370 participants
INTERVENTIONAL
Palo Alto, United States +4 more
Started: Feb 1, 2026
Completed Clinical Trials
15 completed trials for Guanfacine Extended Release in Adhd
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
NCT01069523COMPLETEDPHASE4
42 participants
INTERVENTIONAL
San Antonio, United States
Started: Mar 1, 2010
Inuniv and Working Memory
NCT01177306COMPLETEDPHASE4
18 participants
INTERVENTIONAL
Cary, United States
Started: Jul 1, 2010
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
NCT00997984COMPLETEDPHASE3
340 participants
INTERVENTIONAL
Little Rock, United States +45 more
Started: Nov 17, 2009
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
NCT01500694COMPLETEDPHASE3
215 participants
INTERVENTIONAL
Graz, Austria +59 more
Started: Mar 20, 2012
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
NCT01081132COMPLETEDPHASE3
314 participants
INTERVENTIONAL
Dothan, United States +53 more
Started: Sep 19, 2011
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
NCT03662763COMPLETEDPHASE3
12 participants
INTERVENTIONAL
Maastricht, Netherlands
Started: Sep 1, 2011
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
NCT01081145COMPLETEDPHASE3
528 participants
INTERVENTIONAL
Dothan, United States +80 more
Started: May 11, 2010
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
NCT01985581COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Ottawa, Canada
Started: Oct 1, 2013
Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD
NCT01709695COMPLETEDPHASE4
27 participants
INTERVENTIONAL
New York, United States
Started: Mar 1, 2011
Efficacy and Safety of SPD503 in Combination With Psychostimulants
NCT00734578COMPLETEDPHASE3
461 participants
INTERVENTIONAL
Dothan, United States +60 more
Started: Sep 2, 2008
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01244490COMPLETEDPHASE3
338 participants
INTERVENTIONAL
San Diego, United States +65 more
Started: Jan 17, 2011
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
NCT02048241COMPLETEDPHASE4
11 participants
INTERVENTIONAL
New York, United States
Started: Jul 1, 2011
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
NCT01238575COMPLETEDPHASE4
62 participants
INTERVENTIONAL
Los Angeles, United States +4 more
Started: Dec 1, 2011
Drug Use Study With Intuniv® in European Countries
NCT05870605COMPLETED
5K participants
OBSERVATIONAL
Munich, Germany
Started: Nov 15, 2018
Interventions for Children With Attention and Reading Disorders
NCT01133847COMPLETEDPHASE4
222 participants
INTERVENTIONAL
Cincinnati, United States +1 more
Started: Nov 1, 2010